Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

- PMLiVE

Atlantis Healthcare win grant for patient support programme

Programme will support chronic kidney disease

- PMLiVE

Empowering consumers to drive product development

As a company that focuses on OTC products, we need to be aware of changes taking place in the way that consumers behave, and to focus on their health needs...

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

- PMLiVE

Senior healthcare marketer joins Cello Health Consulting

Robert Stringer brings 20 years’ marketing experience to the role

Sanofi reception

Sanofi and Amgen poised for cholesterol drug sales

Praluent to be assessed by FDA advisory committee later this week

- PMLiVE

Takeda files block on generic diet pill launch

Contrave is succumbing to patent attacks just months after being approved

Shire Basingstoke

Shire rumoured to be pursuing Actelion

Allegedly made a £12.4bn takeover bid for the Swiss biopharma

Redirecting your patient strategy

Pharma’s efforts to update its approach to patients often start at the top

- PMLiVE

Novo brings Xultophy to third European market

Launches diabetes combination of Tresiba-Victoza in the UK

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links